{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:59:58Z","timestamp":1786481998662,"version":"build-2736575974"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Human parainfluenza virus type 1 (hPIV-1) is the most common cause of laryngotracheobronchitis (croup), resulting in tens of thousands of hospitalizations each year in the United States alone. No licensed vaccine is yet available. We have developed murine PIV-1 (Sendai virus [SeV]) as a live Jennerian vaccine for hPIV-1. Here, we describe vaccine testing in healthy 3- to 6-year-old hPIV-1-seropositive children in a dose escalation study. One dose of the vaccine (5 \u00d7 10<jats:sup>5<\/jats:sup>, 5 \u00d7 10<jats:sup>6<\/jats:sup>, or 5 \u00d7 10<jats:sup>7<\/jats:sup>50% egg infectious doses) was delivered by the intranasal route to each study participant. The vaccine was well tolerated by all the study participants. There was no sign of vaccine virus replication in the airway in any participant. Most children exhibited an increase in antibody binding and neutralizing responses toward hPIV-1 within 4 weeks from the time of vaccination. In several children, antibody responses remained above incoming levels for at least 6 months after vaccination. Data suggest that SeV may provide a benefit to 3- to 6-year-old children, even when vaccine recipients have preexisting cross-reactive antibodies due to previous exposures to hPIV-1. Results encourage the testing of SeV administration in young seronegative children to protect against the serious respiratory tract diseases caused by hPIV-1 infections.<\/jats:p>","DOI":"10.1128\/cvi.00618-14","type":"journal-article","created":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T03:08:59Z","timestamp":1420081739000},"page":"298-303","source":"Crossref","is-referenced-by-count":38,"title":["Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children"],"prefix":"10.1128","volume":"22","author":[{"given":"Elisabeth","family":"Adderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Branum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Sealy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart G.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri L.","family":"Surman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Penkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Freiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Slobod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya H.","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall T.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Utech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Allay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sleep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Portner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia L.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"key20180919073757_B1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/00006454-200107000-00003","article-title":"Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States","volume":"20","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"key20180919073757_B2","first-page":"1497","article-title":"Parainfluenza viruses","volume-title":"Fields virology","year":"2007"},{"key":"key20180919073757_B3","first-page":"435","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","year":"1969","journal-title":"Am J Epidemiol"},{"key":"key20180919073757_B4","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1016\/j.vaccine.2005.04.035","article-title":"Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key20180919073757_B5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","year":"1969","journal-title":"Am J Epidemiol"},{"key":"key20180919073757_B6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1099\/0022-1317-72-4-983","article-title":"The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants","volume":"72","year":"1991","journal-title":"J Gen Virol"},{"key":"key20180919073757_B7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1006\/viro.1994.1665","article-title":"Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1","volume":"205","year":"1994","journal-title":"Virology"},{"key":"key20180919073757_B8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1006\/viro.1994.1135","article-title":"Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells","volume":"199","year":"1994","journal-title":"Virology"},{"key":"key20180919073757_B9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0042-6822(90)90201-2","article-title":"The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity","volume":"175","year":"1990","journal-title":"Virology"},{"key":"key20180919073757_B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/viro.1995.1448","article-title":"Human parainfluenza virus-type 1 immunization of infant mice protects from subsequent Sendai virus infection","volume":"212","year":"1995","journal-title":"Virology"},{"key":"key20180919073757_B11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0264-410X(97)00217-X","article-title":"Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one","volume":"15","year":"1997","journal-title":"Vaccine"},{"key":"key20180919073757_B12","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.vaccine.2009.01.041","article-title":"Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073757_B13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/vim.2005.18.255","article-title":"Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus","volume":"18","year":"2005","journal-title":"Viral Immunol"},{"key":"key20180919073757_B14","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1128\/JVI.78.11.6043-6047.2004","article-title":"Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV","volume":"78","year":"2004","journal-title":"J Virol"},{"key":"key20180919073757_B15","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1016\/j.vaccine.2007.10.038","article-title":"Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073757_B16","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.vaccine.2008.04.022","article-title":"Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections","volume":"26","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073757_B17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.vaccine.2011.11.046","article-title":"Sendai virus-based RSV vaccine protects African green monkeys from RSV infection","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073757_B18","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1016\/j.vaccine.2014.03.088","article-title":"Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key20180919073757_B19","first-page":"312","article-title":"Seroepidemiologic studies of Sendai virus infection in Taiwan","volume":"66","year":"1967","journal-title":"Taiwan I Hsueh Hui Tsa Chih"},{"key":"key20180919073757_B20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/BF01275224","article-title":"The development of antibodies against Sendai virus in childhood","volume":"20","year":"1967","journal-title":"Arch Gesamte Virusforsch"},{"key":"key20180919073757_B21","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1016\/j.vaccine.2004.01.053","article-title":"Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults","volume":"22","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073757_B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virusres.2006.03.012","article-title":"Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment","volume":"121","year":"2006","journal-title":"Virus Res"},{"key":"key20180919073757_B23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.virol.2010.12.017","article-title":"Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut","volume":"410","year":"2011","journal-title":"Virology"},{"key":"key20180919073757_B24","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.4049\/jimmunol.171.7.3338","article-title":"Cutting edge: effector memory CD8+ T cells in the lung airways retain the potential to mediate recall responses","volume":"171","year":"2003","journal-title":"J Immunol"},{"key":"key20180919073757_B25","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1016\/j.vaccine.2010.07.068","article-title":"Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1","volume":"28","year":"2010","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00618-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:20Z","timestamp":1627591880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00618-14"}},"subtitle":[],"editor":[{"given":"S. A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,25]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/CVI.00618-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00618-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]}}}